Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

Fig. 1

N-803 treatment increases PD-L1 expression on total CD45+ cells and MDSC populations in the primary tumor, lung, and spleen. 5 × 104 4T1 tumor cells were orthotopically implanted into female Balb/c mice. When tumor volumes reached ~50mm3, mice were treated at days 9 and 13 with 1 μg N-803 (s.c.). Twenty-four hours after the last treatment, PD-L1 expression (geometric mean fluorescence intensity (gMFI)) in the primary tumor, lung parenchyma and vasculature, and spleen was determined by flow cytometry on total CD45+ or CD45 cells (a), G-MDSC/Granulocytes (b), or M-MDSC/Monocytes (c). Graphs show mean ± SD. Data combined from 2 independent experiments, n = 5 mice/group per experiment

Back to article page